ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Anaveon raises $35 million for IL-2 drug

by Ryan Cross
March 8, 2019 | APPEARED IN VOLUME 97, ISSUE 10

 

The Swiss start-up Anaveon has raised about $35 million in its series A financing, led by the British life sciences investor Syncona and supported by the Novartis Venture Fund. The biotech is developing antibody agonists of the interleukin-2 receptor, with the goal of boosting the immune system’s ability to attack tumors in combination with other cancer therapies. Anaveon was founded in 2017 by IL-2 expert Onur Boyman, from the University of Zurich, and Andreas Katopodis, a former R&D director at Novartis.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment